Bacterin International Announces Second Quarter and Six Months 2012 Financi... (elow for further information on this non...)

Bacterin International Announces Second Quarter and Six Months 2012 Financial Results

Date:8/9/2012

elow for further information on this non-GAAP measure.

Bacterin International Holdings, Inc.

Reconciliation of Net (Loss) Income From Operations to EBITDA

(Unaudited)Three Months Ended June 30,Six Months Ended June 30,2012201120122011 Net Loss from ops(347,357)(279,997)(1,620,520)(2,216,296) Depreciation95,20662,533214,280115,205 Allocated depreciation94,48694,486188,972188,972 Stock option comp190,055-385,587381,199 Non-cash stock comp(24,069)157,485304,184388,4758,32134,507(527,497)(1,142,445)

About Bacterin International HoldingsBacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking StatementsThis news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or
'/>"/>

SOURCE Bacterin International Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss
2. Bacterin International Signs Its Third National GPO Contract with Novation
3. Bacterin International Signs Its Fourth National GPO Contract with the Premier healthcare alliance
4. Bacterin International Holdings, Inc. Schedules Second Quarter 2012 Financial Earnings Conference Call
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
8. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Chindex International, Inc. to Report First Quarter 2012 Financial Results
11. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH

Post Your Comments:

(Date:6/17/2013)... Perrigo Company (NYSE: PRGO ; ... agreement to acquire and has completed the acquisition of ... Fera Pharmaceuticals, LLC and its affiliates (Fera), a privately-held, ... pharmaceutical company. The acquired portfolio, including nine prescription ANDA ... during calendar year 2012. Terms of the transaction include ...

(Date:6/17/2013)... , June 17, 2013 AbbVie (NYSE: ... from a Phase I study of ABT-199/GDC-0199, an ... patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), ... High-risk CLL patients are those with deletions of ... fludarabine therapy. These data were presented at the ...

(Date:6/17/2013)... -- Life Technologies Corporation (NASDAQ: LIFE ... iPSC Reprogramming Vectors , the world,s first product to ... developers a Nobel Prize in 2012 for the ability ... embryonic state. Scientists use induced pluripotent stem ... somatic cells. The iPSCs can then be differentiated into ...

Breaking Medicine Technology:Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 2 Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 3 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 2 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 3 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 4 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 5 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 6 Life Technologies Expands Range of Stem Cell Reprogramming Solutions 2 Life Technologies Expands Range of Stem Cell Reprogramming Solutions 3

[0] Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million [0] AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting [0] Life Technologies Expands Range of Stem Cell Reprogramming Solutions

... " Two Years and Counting " White Paper ... Milestones and Educational Needs Elsevier ... more than 1,300 healthcare organizations, today announced the addition of a ... its eBook, A Guide to Education and Training for ICD-10 ...

... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... discovering breakthrough treatments for human disease, announced positive, ... 2 study in carcinoid syndrome with LX1032 ... condition caused by neuroendocrine tumors that usually originate ...

Cached Medicine Technology:Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 2 Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 3 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 2 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 3 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 4 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 5

Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome

(Date:6/17/2013)... New York (PRWEB) June 18, 2013 ... has more physicians listed in New York magazine's ... In the latest survey, 209 NewYork-Presbyterian physicians from ... fortunate to have some of the nation's best ... J. Corwin, CEO of NewYork-Presbyterian Hospital. "We are ...

(Date:6/17/2013)... and Drug Administration (FDA) imposes new graphic warning ... First Amendment challenge if they depict health consequences ... evidence, says a Georgetown University Medical Center public ... warning labelswhich combine images with health warningsare a ... other countries, but the tobacco industry argues they ...

(Date:6/17/2013)... MA (PRWEB) June 17, 2013 Daimer ... robust steam cleaner equipment , such as expertly designed ... launched the KleenJet® Pro Plus 200S for apartment dwellers ... up to 310°F in 15 minutes and pressure levels ... effectively. The machine can be used to clean carpet ...

(Date:6/17/2013)... Bust’DD (pronounced ‘busted’), a new company that ... women with large busts, will soon launch their crowdfunding campaign ... understand the problem of ill-fitting bras and want to offer ... is to raise at least $25,000 to create their beta ... on a wide scale. , In order to kick off ...

(Date:6/17/2013)... (PRWEB) June 17, 2013 Today, ... stand-alone HRAs for small businesses . Zane Benefits, ... employer sponsored health benefits, is the leader in ... arrangements . , According to Zane Benefits’ website, ... Accounts or HRAs, offer small businesses an affordable ...

Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List 2 Health News:Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge? 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 3 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 2 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 3 Health News:Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses 2

[0] NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List [0] Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge?[0] Daimer Ships Vapor Steam Cleaner For Homeowners [0] Arizona Startup Bust’DD Looking to Start a BRAvolution [0] Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses

... , , , ... , the global leader in thin computing and client virtualization, today announced ... Smiles is a rapidly-growing company whose mission is to bring quality dental ... first office in 2002 in Atlanta, GA, the network has demonstrated substantial ...

... , , , ... Health, Inc. (Nasdaq: GHDX ) today announced that Kim ... Adams 29th Annual Global Growth Conference in Boston, on Thursday, August ... access the live and subsequently archived webcast of the presentation, visit ...

... , , , ... Aug. 6 CSC (NYSE: CSC ... company as a preferred provider to help member hospitals comply with the ... U.S. federal government stimulus package. Under the ARRA, hospitals will receive incentive ...

... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... of three MedCounselor consumer drug information modules for pharmacies and ... to take medications safely, assists in identifying unknown tablets or ... indispensable in helping to increase consumer compliance to their drug ...

... , KIBBUTZ SHAMIR, Israel, Aug. 6 Shamir ... to issue its second quarter of 2009 earnings results on Thursday, August ... at 11:00 A.M. EDT that morning. , , ... listen live, please go to www.kcsa.com approximately five ...

... Va., Aug. 6 Sunrise Senior Living, Inc. (NYSE: ... second quarter of 2009. Sunrise will host a conference call ... discuss the financial results. , , "Our restructuring ... expense controls. In recent weeks we have seen a modest lift ...

Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs)Genomic Health to Present at Canaccord Adams 29th Annual Global Growth Conference CSC to Help Georgia Hospital Association Members Achieve 'Meaningful Use' of Electronic Health Records Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results Sunrise Reports Financial Results for Second-Quarter 2009

... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...

Bacterial/Viral Filters for Anesthesia and Respiratory Applications...

Medicine Products:

Medisize Ulti-Mist Filter 30303 Filter 5096 Filter 303HEPA Filter